GEM RA
/ PolyNeuroS
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
October 04, 2021
GABRINOX2: Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients
(clinicaltrials.gov)
- P2; N=210; Not yet recruiting; Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Clinical • New P2 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • MRI
September 21, 2021
SIRCCA: SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
(clinicaltrials.gov)
- P2/3; N=89; Active, not recruiting; Sponsor: Sirtex Medical; Trial completion date: Jun 2021 ➔ Nov 2021; Trial primary completion date: Jun 2021 ➔ Nov 2021
Clinical • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor
December 31, 2020
GABRINOX: First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.
(clinicaltrials.gov)
- P1/2; N=78; Completed; Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle; Active, not recruiting ➔ Completed; N=60 ➔ 78; Trial completion date: Dec 2021 ➔ Dec 2020
Clinical • Enrollment change • Trial completion • Trial completion date • Gastrointestinal Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer
December 31, 2020
GABRINOX-ART: Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
(clinicaltrials.gov)
- P2; N=103; Recruiting; Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor
September 30, 2020
GABRINOX-ART: Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
(clinicaltrials.gov)
- P2; N=103; Not yet recruiting; Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Clinical • New P2 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor
April 13, 2018
SIRCCA: SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
(clinicaltrials.gov)
- P2/3; N=180; Recruiting; Sponsor: Sirtex Medical; Trial completion date: Dec 2019 ➔ Jun 2021; Trial primary completion date: Dec 2019 ➔ Jun 2021
Trial completion date • Trial primary completion date • Biliary Cancer • Biosimilar • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor
December 26, 2019
GABRINOX: First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.
(clinicaltrials.gov)
- P1/2; N=60; Active, not recruiting; Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle; Recruiting ➔ Active, not recruiting; Trial completion date: Mar 2020 ➔ Dec 2021
Clinical • Enrollment closed • Trial completion date
October 31, 2019
SIRCCA: SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
(clinicaltrials.gov)
- P2/3; N=89; Active, not recruiting; Sponsor: Sirtex Medical; Recruiting ➔ Active, not recruiting; N=180 ➔ 89
Clinical • Enrollment change • Enrollment closed
1 to 8
Of
8
Go to page
1